Works by Kletting, Peter

Results: 27

Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting.

Published in:

PLoS ONE, 2022, v. 17, n. 4, p. 1, doi. 10.1371/journal.pone.0266906

By:

Yousefzadeh-Nowshahr, Elham;
Winter, Gordon;
Bohn, Peter;
Kneer, Katharina;
von Arnim, Christine A. F.;
Otto, Markus;
Solbach, Christoph;
Anderl-Straub, Sarah;
Polivka, Dörte;
Fissler, Patrick;
Strobel, Joachim;
Kletting, Peter;
Riepe, Matthias W.;
Higuchi, Makoto;
Glatting, Gerhard;
Ludolph, Albert;
Beer, Ambros J.

Publication type:

Article

Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.245068

By:

Jiménez-Franco, Luis David;
Glatting, Gerhard;
Prasad, Vikas;
Weber, Wolfgang A.;
Beer, Ambros J.;
Kletting, Peter

Publication type:

Article

Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.245068

By:

Jiménez-Franco, Luis David;
Glatting, Gerhard;
Prasad, Vikas;
Weber, Wolfgang A.;
Beer, Ambros J.;
Kletting, Peter

Publication type:

Article

Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.245068

By:

Jiménez-Franco, Luis David;
Glatting, Gerhard;
Prasad, Vikas;
Weber, Wolfgang A.;
Beer, Ambros J.;
Kletting, Peter

Publication type:

Article

Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.245068

By:

David Jiménez-Franco, Luis;
Glatting, Gerhard;
Prasad, Vikas;
Weber, Wolfgang A.;
Beer, Ambros J.;
Kletting, Peter

Publication type:

Article

Modeling and Predicting Tumor Response in Radioligand Therapy.

Published in:

Journal of Nuclear Medicine, 2019, v. 60, n. 1, p. 65, doi. 10.2967/jnumed.118.210377

By:

Kletting, Peter;
Thieme, Anne;
Eberhardt, Nina;
Rinscheid, Andreas;
D’Alessandria, Calogero;
Allmann, Jakob;
Wester, Hans-Jürgen;
Tauber, Robert;
Beer, Ambros J.;
Glatting, Gerhard;
Eiber, Matthias

Publication type:

Article

Optimized Peptide Amount and Activity for 90Y-Labeled DOTATATE Therapy.

Published in:

Journal of Nuclear Medicine, 2016, v. 57, n. 4, p. 503, doi. 10.2967/jnumed.115.164699

By:

Kletting, Peter;
Kull, Thomas;
Maaβ, Christian;
Malik, Noeen;
Luster, Markus;
Beer, Ambros J.;
Glatting, Gerhard

Publication type:

Article

Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model.

Published in:

Journal of Nuclear Medicine, 2010, v. 51, n. 3, p. 484, doi. 10.2967/jnumed.109.067546

By:

Kletting, Peter;
Kull, Thomas;
Bunjes, Donald;
Mahren, Bettina;
Luster, Markus;
Reske, Sven N.;
Glatting, Gerhard

Publication type:

Article

Improving Anti-CD45 Antibody Radioimmunotherapy Using a Physiologically Based Pharmacokinetic Model.

Published in:

Journal of Nuclear Medicine, 2009, v. 50, n. 2, p. 296, doi. 10.2967/jnumed.108.054189

By:

Kletting, Peter;
Bunjes, Donald;
Reske, Sven N.;
Glatting, Gerhard

Publication type:

Article

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry.

Published in:

EJNMMI Physics, 2020, v. 7, n. 1, p. 1, doi. 10.1186/s40658-020-00311-0

By:

Rinscheid, Andreas;
Kletting, Peter;
Eiber, Matthias;
Beer, Ambros J.;
Glatting, Gerhard

Publication type:

Article

A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice.

Published in:

Pharmaceutics, 2021, v. 13, n. 12, p. 2132, doi. 10.3390/pharmaceutics13122132

By:

Zaid, Nouran R. R.;
Kletting, Peter;
Winter, Gordon;
Prasad, Vikas;
Beer, Ambros J.;
Glatting, Gerhard

Publication type:

Article

Important pharmacokinetic parameters for individualization of 177Lu‐PSMA therapy: A global sensitivity analysis for a physiologically‐based pharmacokinetic model.

Published in:

Medical Physics, 2021, v. 48, n. 2, p. 556, doi. 10.1002/mp.14622

By:

Hardiansyah, Deni;
Kletting, Peter;
Begum, Nusrat J.;
Eiber, Matthias;
Beer, Ambros J.;
Pawiro, Supriyanto A.;
Glatting, Gerhard

Publication type:

Article

Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy.

Published in:

Medical Physics, 2019, v. 46, n. 12, p. 5861, doi. 10.1002/mp.13846

By:

Rinscheid, Andreas;
Kletting, Peter;
Eiber, Matthias;
Beer, Ambros J.;
Glatting, Gerhard

Publication type:

Article

Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk.

Published in:

Medical Physics, 2018, v. 45, n. 8, p. 3516, doi. 10.1002/mp.13049

By:

Jiménez‐Franco, Luis David;
Kletting, Peter;
Beer, Ambros J.;
Glatting, Gerhard

Publication type:

Article

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.

Published in:

PLoS ONE, 2016, v. 11, n. 9, p. 1, doi. 10.1371/journal.pone.0162303

By:

Kletting, Peter;
Schuchardt, Christiane;
Kulkarni, Harshad R.;
Shahinfar, Mostafa;
Singh, Aviral;
Glatting, Gerhard;
Baum, Richard P.;
Beer, Ambros J.

Publication type:

Article

The role of patient-based treatment planning in peptide receptor radionuclide therapy.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2016, v. 43, n. 5, p. 871, doi. 10.1007/s00259-015-3248-6

By:

Hardiansyah, Deni;
Maass, Christian;
Attarwala, Ali;
Müller, Berthold;
Kletting, Peter;
Mottaghy, Felix;
Glatting, Gerhard

Publication type:

Article

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225.

Published in:

EJNMMI Research, 2022, v. 12, n. 1, p. 1, doi. 10.1186/s13550-022-00935-6

By:

Meyer, Catherine;
Prasad, Vikas;
Stuparu, Andreea;
Kletting, Peter;
Glatting, Gerhard;
Miksch, Jonathan;
Solbach, Christoph;
Lueckerath, Katharina;
Nyiranshuti, Lea;
Zhu, Shaojun;
Czernin, Johannes;
Beer, Ambros J.;
Slavik, Roger;
Calais, Jeremie;
Dahlbom, Magnus

Publication type:

Article

A population-based method to determine the time-integrated activity in molecular radiotherapy.

Published in:

EJNMMI Physics, 2021, v. 8, n. 1, p. 1, doi. 10.1186/s40658-021-00427-x

By:

Hardiansyah, Deni;
Riana, Ade;
Kletting, Peter;
Zaid, Nouran R. R.;
Eiber, Matthias;
Pawiro, Supriyanto A.;
Beer, Ambros J.;
Glatting, Gerhard

Publication type:

Article

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model.

Published in:

Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-56603-8

By:

Begum, Nusrat J.;
Glatting, Gerhard;
Wester, Hans-Jürgen;
Eiber, Matthias;
Beer, Ambros J.;
Kletting, Peter

Publication type:

Article

Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.

Published in:

Medical Physics, 2016, v. 43, n. 9, p. 5145, doi. 10.1118/1.4961012

By:

Hardiansyah, Deni;
Guo, Wei;
Kletting, Peter;
Mottaghy, Felix M.;
Glatting, Gerhard

Publication type:

Article

A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculation.

Published in:

Medical Physics, 2013, v. 40, n. 8, p. 082502, doi. 10.1118/1.4812684

By:

Fernández, María;
Hänscheid, Heribert;
Mauxion, Thibault;
Bardiès, Manuel;
Kletting, Peter;
Glatting, Gerhard;
Lassmann, Michael

Publication type:

Article

Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy.

Published in:

Medical Physics, 2012, v. 39, n. 9, p. 5708, doi. 10.1118/1.4747266

By:

Kletting, Peter;
Müller, Berthold;
Erentok, Bahar;
Schmaljohann, Jörn;
Behrendt, Florian F.;
Reske, Sven N.;
Mottaghy, Felix M.;
Glatting, Gerhard

Publication type:

Article

Optimal preloading in radioimmunotherapy with anti-CD45 antibody.

Published in:

Medical Physics, 2011, v. 38, n. 5, p. 2572, doi. 10.1118/1.3581059

By:

Kletting, Peter;
Kull, Thomas;
Bunjes, Donald;
Luster, M.;
Reske, Sven N.;
Glatting, Gerhard

Publication type:

Article

Choosing the optimal fit function: Comparison of the Akaike information criterion and the F-test.

Published in:

Medical Physics, 2007, v. 34, n. 11, p. 4285, doi. 10.1118/1.2794176

By:

Glatting, Gerhard;
Kletting, Peter;
Reske, Sven N.;
Hohl, Kathrin;
Ring, Christina

Publication type:

Article

Optimization of Radiolabeling of a [ 90 Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation.

Published in:

Cancers, 2023, v. 15, n. 14, p. 3660, doi. 10.3390/cancers15143660

By:

Winter, Gordon;
Hamp-Goldstein, Carmen;
Fischer, Gabriel;
Kletting, Peter;
Glatting, Gerhard;
Solbach, Christoph;
Herrmann, Hendrik;
Sala, Elisa;
Feuring, Michaela;
Döhner, Hartmut;
Beer, Ambros J.;
Bunjes, Donald;
Prasad, Vikas

Publication type:

Article

Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.

Published in:

EJNMMI Research, 2016, v. 6, n. 1, p. 1, doi. 10.1186/s13550-016-0185-8

By:

Maaß, Christian;
Sachs, Jan;
Hardiansyah, Deni;
Mottaghy, Felix;
Kletting, Peter;
Glatting, Gerhard

Publication type:

Article

Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy.

Published in:

PLoS ONE, 2015, v. 10, n. 5, p. 1, doi. 10.1371/journal.pone.0127934

By:

Kletting, Peter;
Maaß, Christian;
Reske, Sven;
Beer, Ambros J.;
Glatting, Gerhard

Publication type:

Article

Works by Kletting, Peter

Quantitative analysis of regional distribution of tau pathology with <sup>11</sup>C-PBB3-PET in a clinical setting.

Effect of tumor perfusion and receptor density on tumor control probability in <sup>177</sup>Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment.

Effect of tumor perfusion and receptor density on tumor control probability in <sup>177</sup>Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment.

Effect of tumor perfusion and receptor density on tumor control probability in <sup>177</sup>Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment.

Effect of tumor perfusion and receptor density on tumor control probability in <sup>177</sup>Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment.

Modeling and Predicting Tumor Response in Radioligand Therapy.

Optimized Peptide Amount and Activity for 90Y-Labeled DOTATATE Therapy.

Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model.

Improving Anti-CD45 Antibody Radioimmunotherapy Using a Physiologically Based Pharmacokinetic Model.

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry.

A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice.

Important pharmacokinetic parameters for individualization of <sup>177</sup>Lu‐PSMA therapy: A global sensitivity analysis for a physiologically‐based pharmacokinetic model.

Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in <sup>177</sup>Lu‐PSMA therapy.

Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk.

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for <sup>177</sup>Lu-Labeled PSMA-Targeting Peptides.

The role of patient-based treatment planning in peptide receptor radionuclide therapy.

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225.

A population-based method to determine the time-integrated activity in molecular radiotherapy.

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model.

Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.

A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculation.

Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy.

Optimal preloading in radioimmunotherapy with anti-CD45 antibody.

Choosing the optimal fit function: Comparison of the Akaike information criterion and the F-test.

Optimization of Radiolabeling of a [ 90 Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation.

Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.

Physiologically Based Pharmacokinetic Modeling Is Essential in <sup>90</sup>Y-Labeled Anti-CD66 Radioimmunotherapy.